Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated tau PET binding in both medial temporal lobe structures and the neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum [82,130–141].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P-tau [82,83,115]; however, the correlation is imperfect.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we examined the influence of sex to modify the well-characterized cross-sectional association between regional tau PET and global Aβ PET.14–16”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [131]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 2×
“The family of penalized regression fit here is the elastic net penalty (27): the L1 penalty component enforces sparsity (that is, many bs will be identically 0, not included in the model) (26), whereas the L2 penalty allows highly correlated variables to enter the model simultaneously (27).”
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The specificity of this relationship strengthens the argument that the identified relationships are disease-specific: elevated tau in the CSF is associated with tau deposition within regions known to be sensitive to AD-related tauopathy (2).”
InfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 2×
“The Aβ imaging literature has grown over the past decade (4), whereas tau imaging is a relatively new addition to the field.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Research works printed but not linked: 1
- 50. Roussas GG A First Course in Mathematical Statistics Addison-Wesley Pub. Co. Reading, MA 1973
Cited by
Items 101–200 of 736
Tau‐PET uptake: Regional variation in average SUVR and impact of amyloid deposition
Vemuri, P., Lowe, V. J., Knopman, D. S., Senjem, M. L., Kemp, B. J., Schwarz, C. G., Przybelski, S. A., Machulda, M. M., Petersen, R. C., & Jack, C. R. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.010 · Cited by 117
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE
Hampel, H., O’Bryant, S. E., Castrillo, J. I., Ritchie, C., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R. A., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.112 · Cited by 115
“New diagnostic solutions that allow non-invasive neuroimaging of pathological and pathophysiological findings in AD could support not only the evaluation of disease processes, but also help in the development of therapies targeting either Aβ or tau (120) and/or other mechanisms.”
Franzmeier, N., Düzel, E., Jessen, F., Buerger, K., Levin, J., Duering, M., Dichgans, M., Haass, C., Suárez-Calvet, M., Fagan, A. M., et al. (2018) · Brain · doi:10.1093/brain/awy008 · Cited by 115
“Since EYO is not available in spor- adic Alzheimer’s disease subjects, we used CSF total tau levels as a marker of disease severity that is closely linked to neu- rodegeneration and memory decline (Brier et al., 2016).”
MethodSelf-citationDisease staging of Alzheimer’s disease using a CSF-based biomarker model
Salvadó, G., Horie, K., Barthélemy, N. R., Vogel, J. W., Pichet Binette, A., Chen, C. D., Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00599-y · Cited by 113
“12–17), p-tau217 (refs.”
Self-citation[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging
Marquié, M., Siao Tick Chong, M., Antón-Fernández, A., Verwer, E. E., Sáez-Calveras, N., Meltzer, A. C., Ramanan, P., Amaral, A. C., Gonzalez, J., Normandin, M. D., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1740-8 · Cited by 109
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108
Mullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Advances and considerations in AD tau-targeted immunotherapy
Bittar, A., Bhatt, N., & Kayed, R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 104
Alzheimer's disease disrupts alpha and beta-band resting-state oscillatory network connectivity
Koelewijn, L., Bompas, A., Tales, A., Brookes, M. J., Muthukumaraswamy, S. D., Bayer, A. J., & Singh, K. D. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.04.018 · Cited by 109
“However, patterns of tau binding correlate better with both healthy ageing and AD than amyloid-beta (Brier et al. 2016; Ossenkoppele et al. 2016), and there is greater uptake of tau in ApoE4 carriers (carriers of the gene most strongly associated with the risk of developing AD) than non-carriers (Ossenkoppele et al.”
BackgroundInfluentialA novel electrochemical aptamer–antibody sandwich assay for the detection of tau-381 in human serum
Shui, B., Tao, D., Cheng, J., Mei, Y., Jaffrezic-Renault, N. J., & Guo, Z. (2018) · The Analyst · doi:10.1039/c8an00527c · Cited by 103
Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Machulda, M. M., et al. (2019) · Brain · doi:10.1093/brain/awz025 · Cited by 97
“…the obser- vations of others that elevated regional flortaucipir SUVR is contingent on the presence of elevated global PIB SUVR (Johnson et al., 2015; Brier et al., 2016; Cho et al., 2016; Ossenkoppele et al., 2016; Scholl et al., 2016; Schwarz et al., 2016; Marks et al., 2017; Pontecorvo et al.,…”
BackgroundLoss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions
Strain, J. F., Smith, R. X., Beaumont, H., Roe, C. M., Gordon, B. A., Mishra, S., Adeyemo, B., Christensen, J. J., Su, Y., Morris, J. C., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005864 · Cited by 97
“Associations between WM integrity and Aβ have not been consistently found across the literature.(9) In unadjusted analyses, Aβ may serve as a proxy measure for other pathologies (e.”
BackgroundMethodSelf-citationKong, F., Jiang, X., Wang, R., Zhai, S., Zhang, Y., & Wang, D. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01967-2 · Cited by 105
Al-Hilaly, Y. K., Pollack, S. J., Vadukul, D. M., Citossi, F., Rickard, J. E., Simpson, M., Storey, J. M. D., Harrington, C. R., Wischik, C. M., & Serpell, L. C. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.09.007 · Cited by 96
Hansson, O., Grothe, M. J., Strandberg, T. O., Ohlsson, T., Hägerström, D., Jögi, J., Smith, R., & Schöll, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00167 · Cited by 95
“…vivo tau PET ligands in AD supports a typical involvement of the inferior and lateral temporal lobes, precuneus and posterior cingulate, as well as occipital and lateral parietal lobes (Brier et al., 2016; Ishiki et al., 2015; Johnson et al., 2016; Ossenkoppele et al., 2016; Schwarz et al., 2016).”
BackgroundComparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Mattsson, N., Smith, R., Strandberg, O., Palmqvist, S., Schöll, M., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004887 · Cited by 95
“These participants were eligible for inclusion if they (1) were referred to the memory clinics because of cognitive impairment, (2) did not fulfil the criteria for dementia, (3) scored 24–30 points on the MMSE, (4) had objective memory impairment according to delayed word list recall, (5) were aged 60–80 years, (6) ha…”
Jin, D., Zhou, B., Han, Y., Ren, J., Han, T., Liu, B., Lu, J., Song, C., Wang, P., Wang, D., et al. (2020) · Advanced Science · doi:10.1002/advs.202000675 · Cited by 92
Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging
Lee, D. H., Lee, P., Seo, S. W., Roh, J. H., Oh, M., Oh, J. S., Oh, S. J., Kim, J. S., & Jeong, Y. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.11.053 · Cited by 105
“However, our model addresses not only neuronal degeneration (structural atrophy) but also proteinopathies prior to neurodegeneration (Bejanin et al., 2017; Brier et al., 2016; Rolstad et al., 2011).”
Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease
Tanner, J. A., Iaccarino, L., Edwards, L., Asken, B. M., Gorno-Tempini, M. L., Kramer, J. H., Pham, J., Perry, D. C., Possin, K., Malpetti, M., et al. (2022) · Brain · doi:10.1093/brain/awac229 · Cited by 91
Pereira, J. B., Ossenkoppele, R., Palmqvist, S., Strandberg, T. O., Smith, R., Westman, E., & Hansson, O. (2019) · eLife · doi:10.7554/elife.50830 · Cited by 91
Demirtaş, M., Falcon, C., Tucholka, A., Gispert, J. D., Molinuevo, J. L., & Deco, G. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.08.006 · Cited by 89
Adams, J. N., Lockhart, S. N., Li, L., & Jagust, W. J. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhy078 · Cited by 89
“2017), and reduced cognitive function (Brier et al. 2016; Maass, Lockhart et al. 2017), it is likely that tau is a closer link than amyloid-β to the neurodegenerative processes in AD.”
BackgroundBuckley, R. F., Mormino, E. C., Chhatwal, J., Schultz, A. P., Rabin, J. S., Rentz, D. M., Acar, D., Properzi, M. J., Dumurgier, J., Jacobs, H., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.019 · Cited by 88
The association between tau PET and retrospective cortical thinning in clinically normal elderly
LaPoint, M. R., Chhatwal, J. P., Sepulcre, J., Johnson, K. A., Sperling, R. A., & Schultz, A. P. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.049 · Cited by 87
Neural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J.-P. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 86
“In addition, several studies identified early bio-markers of AD by measuring levels of Aβ in cerebrospinal fluid (CSF) and blood as well as early detection of Aβ and tau deposits by brain imaging (e.g., positron emission tomography (PET) (Brier et al., 2016).”
BackgroundPlasma p‐tau immunoassays in clinical research for Alzheimer's disease
Teunissen, C. E., Kolster, R., Triana‐Baltzer, G., Janelidze, S., Zetterberg, H., & Kolb, H. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14397 · Cited by 103
Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome
Neale, N., Padilla, C., Fonseca, L. M., Holland, T., & Zaman, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.10.022 · Cited by 86
“In the general population, tau pathology is a more accurate marker for cognitive decline in AD than amyloid pathology (Brier et al., 2016).”
BackgroundGordon, B. A., McCullough, A. A., Mishra, S., Blazey, T., Su, Y., Christensen, J., Dincer, A., Jackson, K., Hornbeck, R. C., Morris, J. C., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.02.003 · Cited by 103
Self-citationZhou, Q., Li, S., Li, M., Ke, D., Wang, Q., Yang, Y., Liu, G., Wang, X., Liu, E., & Wang, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103970 · Cited by 101
“29 Reducing endogenous tau can improve excitotoxicity and cognitive impairment caused by A b .”
Uchida, Y., Kan, H., Sakurai, K., Oishi, K., & Matsukawa, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.938092 · Cited by 100
“However, recent clinicopathological and radiological data suggest that tau pathology, not Aβ pathology, closely links with onset and progression of Alzheimer’s symptoms (Brier et al., 2016; Aillaud and Funke, 2022) though the relationship and interplay between Aβ and tau pathologies remain controversial (Pourhamzeh et…”
BackgroundAssociations Between Tau, β-Amyloid, and Cognition in Parkinson Disease
Winer, J. R., Maaß, A., Pressman, P., Stiver, J., Schonhaut, D. R., Baker, S. L., Kramer, J. H., Rabinovici, G. D., & Jagust, W. J. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3713 · Cited by 95
Tau pathology and cognitive reserve in Alzheimer's disease
Hoenig, M. C., Bischof, G. N., Hammes, J., Faber, J., Fließbach, K., van Eimeren, T., & Drzezga, A. E. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.004 · Cited by 91
Shimada, H., Kitamura, S., Shinotoh, H., Endo, H., Niwa, F., Hirano, S., Kimura, Y., Zhang, M., Kuwabara, S., Suhara, T., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.009 · Cited by 81
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 93
Can exercise training teach us how to treat Alzheimer's disease?
Huuha, A. M., Norevik, C. S., Moreira, J. B. N., Kobro-Flatmoen, A., Scrimgeour, N., Kivipelto, M., Van Praag, H., Ziaei, M., Sando, S. B., Wisløff, U., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101559 · Cited by 79
Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79
Nathan, P. J., Lim, Y. Y., Abbott, R., Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Bartrés‐Faz, D., Didic, M., Farotti, L., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.013 · Cited by 94
Wang, H., Sun, X., Zhang, N., Ji, Z., Ma, Z., Fu, Q., Qu, R., & Ma, S. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.10.001 · Cited by 78
Tao, D., Shui, B., Gu, Y., Cheng, J., Zhang, W., Jaffrezic-Renault, N. J., Song, S., & Guo, Z. (2019) · Biosensors · doi:10.3390/bios9030084 · Cited by 79
Astrocytic propagation of Tau in the context of Alzheimer's disease
Fleeman, R. M., & Proctor, E. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.645233 · Cited by 75
“Accumulation of pathological tau in the brain is clinically significant as it correlates with progression of cognitive symptoms better than other markers, including Aβ (Arriagada et al., 1992; Brier et al., 2016).”
BackgroundYang, S., Chiu, M., Chen, T., & Horng, H. E. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0075-7 · Cited by 80
Association of Aβ with ceramide-enriched astrosomes mediates Aβ neurotoxicity
Elsherbini, A., Kirov, A. S., Dinkins, M. B., Wang, G., Qin, H., Zhu, Z., Tripathi, P., Crivelli, S. M., & Bieberich, E. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00931-8 · Cited by 72
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
Deters, K. D., Risacher, S. L., Kim, S., Nho, K., West, J. D., Blennow, K., Zetterberg, H., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161114 · Cited by 72
Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E., Christian, B. T., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00139-3 · Cited by 70
Self-citationCiccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69
Chandra, A., Farrell, C. M., Wilson, H., Dervenoulas, G., de Natale, E. R., & Politis, M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.007 · Cited by 76
Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 69
Day, G. S., Gordon, B. A., Jackson, K., Christensen, J. J., Rosana Ponisio, M., Su, Y., Ances, B. M., Benzinger, T. L. S., & Morris, J. C. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000196 · Cited by 68
“Gerstmann syndrome (partial/complete) 5 (100)w 0 – Apraxia 4 (80)w 0 – Memory impairment 4 (80) 22 (100) – Mini-Mental State Examination, median (range) 25 (19-29)* 27 (14-30) 30 (27-30)w,z Global CDR, median (range) (y) 0.”
Self-citationKoychev, I., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B., Sahakian, B. J., Rowe, J. B., Thomas, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170129 · Cited by 69
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 74
“Tau PET imaging is sensitive and detects early cognitive changes in the preclinical AD than A PET imaging [104, 105].”
BackgroundDel Amo, L., Cano, A., Ettcheto, M., Souto, E. B., Espina, M., Camins, A., García, M. L., & Sánchez-López, E. (2021) · Applied Sciences · doi:10.3390/app11094305 · Cited by 67
“Therefore, several studies on biomarkers point out that Tau pathology is intimately related to the progression of neurodegeneration [33].”
BackgroundTracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy
Blackmore, T., Meftah, S., Murray, T. K., Craig, P. J., Blockeel, A., Phillips, K., Eastwood, B., O’Neill, M. J., Marston, H., Ahmed, Z., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0306-2 · Cited by 66
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Van Kolen, K., Theunis, C., Mercken, M., & Kolb, H. C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 64
Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy
Ye, J., Wan, H., Chen, S., & Liu, G. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385847 · Cited by 80
“Studies have demonstrated that tau mediates Aβ-induced toxicity and correlates better with clinical cognitive impairments than Aβ burden (Rapoport et al., 2002; Vossel et al., 2010; Brier et al., 2016).”
Tau pathology in cognitively normal older adults
Ziontz, J., Bilgel, M., Shafer, A. T., Moghekar, A., Elkins, W., Helphrey, J., Gomez, G., June, D., McDonald, M. A., Dannals, R. F., et al. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.07.007 · Cited by 63
“This suggests that tau rather than amyloid deposition may be more strongly associated with cognition, consistent with previous 315 findings [9].”
BackgroundResultKoch, G., Di Lorenzo, F., Loizzo, S., Motta, C., Travaglione, S., Baiula, M., Rimondini, R., Ponzo, V., Bonnì, S., Toniolo, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14204-3 · Cited by 64
Volmar, C.-H., Salah-Uddin, H., Janczura, K. J., Halley, P., Lambert, G., Wodrich, A., Manoah, S., Patel, N. H., Sartor, G. C., Mehta, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707544114 · Cited by 64
Spatial navigation ability predicts progression of dementia symptomatology
Levine, T. F., Allison, S. L., Stojanovic, M., Fagan, A. M., Morris, J. C., & Head, D. M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12031 · Cited by 74
Self-citationGuo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 74
Molecular estimation of neurodegeneration pseudotime in older brains
Mukherjee, S., Heath, L., Preuss, C., Jayadev, S., Garden, G. A., Greenwood, A. K., Sieberts, S. K., De Jager, P. L., Ertekin-Taner, N., Carter, G. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19622-y · Cited by 63
Widespread distribution of tauopathy in preclinical Alzheimer's disease
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.022 · Cited by 64
“Other studies also described regional associations with other core AD biomarkers including beta-amyloidPET (Brier et al., 2016; Lockhart et al., 2017; Sepulcre et al., 2016), CSF tau levels (Chhatwal et al., 2016; Gordon et al., 2016; Wang et al., 2016), gray matter volumes and cortical thinning…”
BackgroundMethodResultSelf-citationWang, Q., Wang, Y., Liu, J., Sutphen, C. L., Cruchaga, C., Blazey, T., Gordon, B. A., Su, Y., Chen, C., Shimony, J. S., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101767 · Cited by 63
“…endpoints, leading to increasing interest in other possible AD-related pathophysiological mechanisms, such as accumulation of intracellular tau (Brier et al., 2016; Fagan et al., 2011; Gordon et al., 2016; Johnson et al., 2016), and more recently, inflammation (Heneka et al., 2015; Holtzman et…”
BackgroundSelf-citationRegional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
Horie, K., Barthélemy, N. R., Mallipeddi, N., Li, Y., Franklin, E. E., Perrin, R. J., Bateman, R. J., & Sato, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01019-z · Cited by 63
Weigand, A. J., Thomas, K. R., Bangen, K. J., Eglit, G. M. L., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, F. T. A. D. N. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12173 · Cited by 59
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 88
Jiang, M., Chi, J., Qiao, Y., Wang, J., Zhang, Z., Liu, J., Sheng, X., & Yuan, L. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107578 · Cited by 72
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 69
“Tau imaging is a more recent development, still being evaluated for clinical use, and is discussed elsewhere.(6,7)”
BackgroundMethodResultInfluentialSleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease
Van Egroo, M., Narbutas, J., Chylinski, D., Villar González, P., Maquet, P., Salmon, E., Bastin, C., Collette, F., & Vandewalle, G. (2019) · Sleep · doi:10.1093/sleep/zsz017 · Cited by 62
Monoclonal Antibodies as Neurological Therapeutics
Gklinos, P., Papadopoulou, M., Stanulovic, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 61
Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Elbatrawy, A. A., Hyeon, S. J., Yue, N., Osman, E. E. A., Choi, S. H., Lim, S., Kim, Y. K., Ryu, H., Cui, M., & Nam, G. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00338 · Cited by 63
Cell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 74
Characterizing the emergence of amyloid and tau burden in Down syndrome
Zammit, M. D., Betthauser, T. J., McVea, A. K., Laymon, C. M., Tudorascu, D. L., Johnson, S. C., Hartley, S. L., Converse, A. K., Minhas, D. S., Zaman, S. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13444 · Cited by 60
“In neurotypical populations, tau has been associated with both A β and cognitive decline, 30 and the associations between tau and cognition have been observed withastrongereffectascomparedtoA β andcognition.”
BackgroundSelf-citationTau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12875 · Cited by 60
“Wefoundthattau-PET,baselinecognition,corticalthickness,p-tau217 levels in blood and CSF, as well as CSF NfL can all individually predict future cognitive decline in patients with amnestic MCI or mild dementia.”
InfluentialGhrelin in Alzheimer’s disease: Pathologic roles and therapeutic implications
Jeon, S. G., Hong, S. B., Nam, Y., Tae, J., Yoo, A., Song, E. J., Kim, K. I., Lee, D., Park, J., Lee, S. M., et al. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100945 · Cited by 58
Cho, Y.-E., Lee, M.-H., & Song, B.-J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169945 · Cited by 57
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
“Interestingly, evidence suggests that accumulation of tau correlates with brain atrophy and clinical symptoms in Alzheimer’s disease patients and other tauopathies (Nelson et al., 2012; Brier et al., 2016; Johnson et al., 2016).”
BackgroundSelf-citationSreenivasmurthy, S. G., Iyaswamy, A., Krishnamoorthi, S., Senapati, S., Malampati, S., Zhu, Z., Su, C.-F., Liu, J., Guan, X.-J., Tong, B. C., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153887 · Cited by 64
Dolatshahi, M., Pourmirbabaei, S., Kamalian, A., Ashraf‐Ganjouei, A., Yaseri, M., & Aarabi, M. H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00560 · Cited by 60
Vitale, F., Giliberto, L., Ruiz, S., Steslow, K., Marambaud, P., & d’Abramo, C. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0585-2 · Cited by 57
Quantitative positron emission tomography in brain research
Heurling, K., Leuzy, A., Jonasson, M., Frick, A., Zimmer, E. R., Nordberg, A. K., & Lubberink, M. (2017) · Brain Research · doi:10.1016/j.brainres.2017.06.022 · Cited by 64
Losev, Y., Frenkel-Pinter, M., Abu-Hussien, M., Viswanathan, G. K., Elyashiv-Revivo, D., Geries, R., Khalaila, I., Gazit, E., & Segal, D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03643-3 · Cited by 52
Comparison of plasma and CSF biomarkers in predicting cognitive decline
Aschenbrenner, A. J., Li, Y., Henson, R. L., Volluz, K., Hassenstab, J., Verghese, P., West, T., Meyer, M. R., Kirmess, K. M., Fagan, A. M., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51670 · Cited by 55
Self-citationThe biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology
Boccardi, M., Gallo, V., Yasui, Y., Vineis, P., Padovani, A., Mosimann, U., Giannakopoulos, P., Gold, G., Dubois, B., Jack, C. R., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.021 · Cited by 54
Kocagöncü, E., Quinn, A. J., Firouzian, A., Cooper, E., Greve, A., Gunn, R. N., Green, G. G. R., Woolrich, M. W., Henson, R. N., Lovestone, S., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.009 · Cited by 57
Iaccarino, L., La Joie, R., Edwards, L., Strom, A., Schonhaut, D. R., Ossenkoppele, R., Pham, J., Mellinger, T., Janabi, M., Baker, S. L., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhaa184 · Cited by 54
“…tau PET uptake correlating with atrophy, glucose hypometabolism, and clinical deficits across the spectrum of disease severity (Bischof et al. 2016; Brier et al. 2016; Cho et al. 2016; Dronse et al. 2016; Johnson et al. 2016; Ossenkoppele et al. 2016; Schöll et al. 2016; Sepulcre et al. 2016; Wang…”
BackgroundResultDisrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer’s disease
Weng, F., & He, L. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.11.015 · Cited by 60
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 72
Nam, Y., Shin, S. J., Kumar, V., Won, J., Kim, S., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00479-4 · Cited by 66
Design principles and fundamental understanding of biosensors for amyloid-β detection
Zhang, Y., Ren, B., Zhang, D., Liu, Y., Zhang, M., Zhao, C., & Zheng, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00344a · Cited by 57
Seo, Y., Park, K., Ha, T., Kim, M. K., Hwang, Y. J., Lee, J.-H., Ryu, H., Choo, H., & Chong, Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00174 · Cited by 54
Florenzano, F., Veronica, C., Ciasca, G., Ciotti, M. T., Pittaluga, A., Olivero, G., Feligioni, M., Iannuzzi, F., Latina, V., Maria Sciacca, M. F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17371 · Cited by 53
Neuroimaging in aging and neurologic diseases
Risacher, S. L., & Saykin, A. J. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00012-1 · Cited by 83
“Tau PET also correlates with CSF levels of amyloid and tau across CN, MCI, and AD participants (Brier et al., 2016).”
BackgroundLish, A. M., Grogan, E. F. L., Benoit, C. R., Pearse, R. V., Heuer, S. E., Luquez, T., Orme, G. A., Galle, P. C., Milinkeviciute, G., Green, K. N., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.034 · Cited by 61
Self-citationPark, K., Kim, M. K., Seo, Y., Ha, T., Yoo, K., Hyeon, S. J., Hwang, Y. J., Lee, J.-H., Ryu, H., Choo, H., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00224 · Cited by 51
The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer’s Disease
Cellai, L., Carvalho, K., Faivre, É., Deleau, A., Vieau, D., Buée, L., Blum, D., Mériaux, C., & Gómez‐Murcia, V. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00520 · Cited by 58
“Although the development and progression of both lesions are involved in the evolution of clinical deficits, the spreading of Tau pathology has been suggested as a more reliable predictor for cognitive impairment (Brier et al., 2016).”
BackgroundKang, J. M., Lee, S., Seo, S., Jeong, H. J., Woo, S., Lee, H., Lee, Y., Yeon, B. K., Shin, D. H., Park, K. H., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.008 · Cited by 52
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 50
Metadata
- Authors
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., & Ances, B. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Benzinger, Tammie L. S.
- Ances, Beau M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-11
- Volume
- 8
- Issue
- 338
- Pages
- 338ra66-338ra66
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5267531
- OpenAlex
- W2353776455
- Cited by
- 734
- References
- 56
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 58 · 2023: 69 · 2022: 64 · 2021: 90 · 2020: 101 · 2019: 80 · 2018: 73 · 2017: 75 · 2016: 23
- FWCI
- 74.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Open Scholarship Institutional Repository (Washington University in St. Louis) (submittedVersion)
- Funders
- NIH (P50AG05681, P01AG003991, P01AG026276, 5P30NS048056, 2UL1TR000448, 5RO1AG04343404)
- NSF (DMS1300280)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, tau PET imaging, cerebrospinal fluid tau, temporal lobe, preclinical Alzheimer's disease, cognitive performance, disease progression, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Male, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.